03378 翰思艾泰－Ｂ
HANXBIO-B
HANXBIO-B
| Register Close | 2025/12/18 IPO Closing in 3 Days |
| Listing Date | 2025/12/23 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Since 2016, the Group has developed a product pipeline comprising of one Core Product and nine other pipeline candidates, which are three clinical stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical stage drug candidates including antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market.
--
The Group’s Core Product HX009 is a bifunctional anti-PD-1 (an immune checkpoint receptor) antibody SIRP fusion protein developed in-house. The Group has completed the Phase I clinical trial of HX009 in Australia and China and it is currently conducting three clinical programs for HX009 in China.
--
As of December 8, 2025, the Group also has two Key Products, namely HX301 and HX044, which are in the clinical stage, focusing on the treatment of cancer.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 18.32M H shares |
| No. of International Offer Shares | 16.49M H shares |
| No. of HK Offer Shares | 1.83M H shares |
| Offer Price | $28.00 - $32.00 |
| Stock Code | 3378 |
| Sponsor(s) | ICBC International Capital Limited |
| Underwriter(s) | ICBC International Securities Limited, China Securities (International) Corporate Finance Company Limited, China Merchants Securities (HK) Co., Limited, Haitong International Securities Company Limited, CCB International Capital Limited, TFI Securities and Futures Limited, ABCI Securities Company Limited, SPDB International Capital Limited, Livermore Holdings Limited, Tiger Brokers (HK) Global Limited, Shanxi Securities International Limited, Beta International Securities Limited |
TIME TABLE
| Application Period | Dec 15 (Mon) - noon, Dec 18 (Thu) |
| Price Determination Date | Dec 19 (Fri) |
| Result Announcement Date | On or before Dec 22 (Mon) |
| Result Announcement Date | On or before Dec 22 (Mon) |
| Result Announcement Date | On or before Dec 23 (Tue) |
| Dealings in Shares commence on | Dec 23, 2025. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $28.00 - $32.00 |
| Capitalization (H Shares) | 3.81B - 4.36B |
| NAV / share ($) | $5.39 - $5.91 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 30.00, the net proceeds raised would be HKD 496.30M, of which |
| 35% : Research and development of Core Product HX009 |
| 33% : Research and development of Key Products HX301 and HX044 |
| 17% : Research and development of other important products |
| 5% : Fund the commercialization or business development activities |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).